Targeting memory loss with aspirin, a molecular mechanism perspective for future therapeutic approaches

被引:3
|
作者
Gholami, Masoumeh [1 ]
Sadegh, Mehdi [1 ]
Koroush-arami, Masoumeh [2 ]
Norouzi, Shaghayegh [3 ]
Arismani, Rasoul Jafari [4 ]
Asadi, Erfan [5 ]
Amini, Mohammad [5 ]
Khodayari, Nahid [1 ]
机构
[1] Arak Univ Med Sci, Fac Med, Dept Physiol, Arak 3848176941, Iran
[2] Iran Univ Med Sci, Sch Adv Technol Med, Dept Neurosci, Tehran, Iran
[3] Univ Kentucky Markey Canc Ctr, Lexington, KY USA
[4] Arak Univ Med Sci, Fac Med, Dept Surg, Arak, Iran
[5] Arak Univ Med Sci, Fac Med, Arak, Iran
关键词
Acetylsalicylic acid; Cyclooxygenase; Dementia; Alzheimer; Synaptic plasticity; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PASSIVE-AVOIDANCE TASK; SENSING ION CHANNELS; ALZHEIMERS-DISEASE; SYNAPTIC PLASTICITY; OXIDATIVE STRESS; PROSTAGLANDIN SYNTHESIS; CYCLOOXYGENASE-2; COX-2; PRIMARY PREVENTION; BRAIN;
D O I
10.1007/s10787-023-01347-1
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Acetylsalicylic acid (ASA), also known as aspirin, was discovered in 1897 as an acetylated form of salicylate. It has been widely used for its anti-inflammatory and antiplatelet effects. It is commonly used for its cardiovascular benefits and is prescribed as secondary prophylaxis after a heart attack. Furthermore, low-dose, long-term ASA is used to reduce the risk of heart attack and stroke in individuals without prior cardiovascular disease. Acetylsalicylic acid acts as a non-selective inhibitor of cyclooxygenase (COX), which inhibits the synthesis of prostaglandins and prevents pro-inflammatory cytokines. Findings suggest that targeting cytokines and growth factors could be a potential therapeutic strategy for reducing neuroinflammation and slowing down the progression of dementia. Additionally, prostaglandins contribute to synaptic plasticity and can act as retrograde messengers in synapses. Research has implicated COX-1, one of the isoforms of the enzyme, in neuroinflammation and neurodegenerative disorders. The inhibition of COX-1 might potentially prevent impairments in working memory and reduce neuroinflammation caused by beta-amyloid proteins in some conditions, such as Alzheimer's disease (AD). Cyclooxygenase-2, an inducible form of the enzyme, is expressed in cortical and hippocampal neurons and is associated with long-term synaptic plasticity. The inhibition or knockout of COX-2 has been shown to decrease long-term potentiation, a process involved in memory formation. Studies have also demonstrated that the administration of COX-2 inhibitors impairs cognitive function and memory acquisition and recall in animal models. There remains a debate regarding the effects of aspirin on dementia and cognitive decline. Although some studies suggest a possible protective effect of non-steroidal anti-inflammatory drugs, including aspirin, against the development of AD, others have shown inconsistent evidence. This review provides an overview of the effects of ASA or its active metabolite salicylate on learning, memory, and synaptic plasticity.
引用
收藏
页码:2827 / 2842
页数:16
相关论文
共 50 条
  • [31] Targeting of Prosurvival Pathways as Therapeutic Approaches against Primary Effusion Lymphomas: Past, Present, and Future
    Granato, Marisa
    Santarelli, Roberta
    Gonnella, Roberta
    Farina, Antonella
    Trivedi, Pankaj
    Faggioni, Alberto
    Cirone, Andmara
    BIOMED RESEARCH INTERNATIONAL, 2015, 2015
  • [32] Biogenic Phytochemicals Modulating Obesity: From Molecular Mechanism to Preventive and Therapeutic Approaches
    Kumar, Vikram
    Singh, Desh Deepak
    Lakhawat, Sudarshan Singh
    Yasmeen, Nusrath
    Pandey, Aishwarya
    Singla, Rajeev K.
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [33] The Emerging Role of MicroRNAs and Autophagy Mechanism in Pancreatic Cancer Progression: Future Therapeutic Approaches
    Koustas, Evangelos
    Trifylli, Eleni-Myrto
    Sarantis, Panagiotis
    Papadopoulos, Nikolaos
    Papanikolopoulos, Konstantinos
    Aloizos, Georgios
    Damaskos, Christos
    Garmpis, Nikolaos
    Garmpi, Anna
    Karamouzis, Michalis, V
    GENES, 2022, 13 (10)
  • [34] EZH2 as a new therapeutic target in brain tumors: Molecular landscape, therapeutic targeting and future prospects
    Paskeh, Mahshid Deldar Abad
    Mehrabi, Atefeh
    Gholami, Mohammad Hossein
    Zabolian, Amirhossein
    Ranjbar, Ehsan
    Saleki, Hossein
    Ranjbar, Adnan
    Hashemi, Mehrdad
    Ertas, Yavuz Nuri
    Hushmandi, Kiavash
    Mirzaei, Sepideh
    Ashrafizadeh, Milad
    Zarrabi, Ali
    Samarghandian, Saeed
    BIOMEDICINE & PHARMACOTHERAPY, 2022, 146
  • [35] Waterlogging Tolerance of Crops: Breeding, Mechanism of Tolerance, Molecular Approaches, and Future Prospects
    Ahmed, F.
    Rafii, M. Y.
    Ismail, M. R.
    Juraimi, A. S.
    Rahim, H. A.
    Asfaliza, R.
    Latif, M. A.
    BIOMED RESEARCH INTERNATIONAL, 2013, 2013
  • [36] Molecular Pathways: Targeting Inhibitor of Apoptosis Proteins in Cancer-From Molecular Mechanism to Therapeutic Application
    Fulda, Simone
    CLINICAL CANCER RESEARCH, 2014, 20 (02) : 289 - 295
  • [37] Noninvasive urine metabolomics of prostate cancer and its therapeutic approaches: a current scenario and future perspective
    Kumar, Deepak
    Nath, Kavindra
    Lal, Hira
    Gupta, Ashish
    EXPERT REVIEW OF PROTEOMICS, 2021, 18 (11) : 995 - 1008
  • [38] A Review of Telomere Attrition in Cancer and Aging: Current Molecular Insights and Future Therapeutic Approaches
    Iskandar, Mina
    Barbero, Miguel Xiao
    Jaber, Muhamed
    Chen, Roy
    Gomez-Guevara, Romulo
    Cruz, Edwin
    Westerheide, Sandy
    CANCERS, 2025, 17 (02)
  • [39] Present and future approaches to Parkinson disease - From molecular insights to new therapeutic avenues
    Fariello, Ruggero G.
    Lieberman, Abraham
    NEUROLOGY, 2006, 67 (07) : S1 - S4
  • [40] Novel treatment planning approaches to enhance the therapeutic ratio: targeting the molecular mechanisms of radiation therapy
    Protopapa, M.
    Kouloulias, V.
    Kougioumtzopoulou, A.
    Liakouli, Z.
    Papadimitriou, C.
    Zygogianni, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (04): : 447 - 456